NasdaqCM - Nasdaq Real Time Price USD

SeaStar Medical Holding Corporation (ICU)

0.2194

+0.0049

(+2.28%)

At close: June 7 at 4:00 PM EDT

0.2270

+0.01

(+3.46%)

After hours: June 7 at 7:49 PM EDT

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation

DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a peer-reviewed article in Nature Scientific Reports that describes the mechanism of action of the Company’s Selective Cytopheretic Device (SCD) in the immunomodulation of excessive inflammation. “Immunomodulatory effects of a cell progre

GlobeNewswire yesterday

ICU
+2.28%
ICUCW
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024

DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will hold a fireside chat at the Virtual Emerging Growth Conference on Wednesday, June 12 at 12:35 p.m. Eastern time (9:35 a.m. Pacific time). During the fireside chat, Mr. Schlorff will provide an overview of SeaStar Medical and th

GlobeNewswire yesterday

ICU
+2.28%
ICUCW
SeaStar Medical Announces 25-for-1 Reverse Stock Split

DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the Company’s 25-for-1 reverse stock split, which will become effective at June 7, 2024 at 5:00 PM EDT. The Company’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on June 10, 2024. SeaS

GlobeNewswire 2 days ago

ICU
+2.28%
ICUCW
Seastar touts positive case studies for selective cytopheretic device

The device is designed to modulate the immune response by targeting and removing pro-inflammatory neutrophils and monocytes.

Medical Device Network 15 days ago

ICUCW
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility

SCD’s ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct DENVER, May 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a manuscript citing four case studies in which critically ill patients bet

GlobeNewswire 17 days ago

ICU
+2.28%
ICUCW
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update

DENVER, May 14, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2024 and provides a business update. “As we guided in late February, we expect initial sales in the coming weeks of Quelimmune™ Pediatric, which is approved for the tre

GlobeNewswire 24 days ago

ICU
+2.28%
ICUCW
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT, a member of the Company’s Quelimmune™ product family) as a bridgin

GlobeNewswire last month

ICU
+2.28%
ICUCW
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update. “It was exceptionally exciting to receive our first FDA approval for Quelimmune™, which is now available for treating critically

GlobeNewswire last month

ICU
+2.28%
ICUCW
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference

DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session. Investors int

GlobeNewswire last month

ICU
+2.28%
ICUCW
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and Sep

GlobeNewswire 2 months ago

ICU
+2.28%
ICUCW
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically il

GlobeNewswire 2 months ago

ICU
+2.28%
ICUCW
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024

March 13 webcast showcasing Quelimmune™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces its sponsorship of an Industry Symposium titled “New Therapies in Pediatric Acute Kidney Injury” on

GlobeNewswire 2 months ago

ICU
+2.28%
ICUCW
Q4 2023 Nuwellis Inc Earnings Call

Q4 2023 Nuwellis Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

ICUCW
Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces publication of a manuscript discussing the role of chronic dysregulated systemic inflammation in heart failure and the potentia

GlobeNewswire 3 months ago

ICU
+2.28%
ICUCW
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribution partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), has received Humanitarian Device Exemption (HDE) from the U.S. Food and Drug Administration (FDA) for Quelimmune™, its pediatric Selective Cytopheretic Device. Quelimmune provides a new therapy option for children wei

GlobeNewswire 3 months ago

ICU
+2.28%
ICUCW

NUWE
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) Approval Order to the Selective Cytopheretic Device (SCD) Pediatric (SCD-PED)

GlobeNewswire 3 months ago

ICU
+2.28%
ICUCW
Unleash Massive Returns With These 3 Top Penny Stocks

Despite a recent decline in the leading economic index, the U.S. economy is positioned for a positive future in 2024. Strong employment and robust stock levels contribute to the optimistic outlook. And, while there may be a slowdown in GDP growth in the second and third quarters, the U.S. Federal Reserve’s forecast of 2.9% growth in the first quarter. This indicates a resilient and promising economic landscape for the United States. These top penny stocks will benefit from this strong economy, i

InvestorPlace 3 months ago

ADVM

ICUCW
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the issuance by the Canadian Intellectual Property Office of Canadian Patent No. 2814586. This new patent has broad claims covering the Company’s Selective Cytopheretic Device (SCD) technology. Its issuance expands SeaStar Medical’s international patent rights and complemen

GlobeNewswire 4 months ago

ICU
+2.28%
ICUCW
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase 10,840,761 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement,

GlobeNewswire 4 months ago

ICU
+2.28%
ICUCW
SeaStar Medical Appoints David A. Green as Chief Financial Officer

DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the appointment of healthcare industry veteran David A. Green as Chief Financial Officer, effective January 10, 2024. Caryl Baron, who has served as Interim CFO since October 2022, will continue with SeaStar Medical as Vice President of Finance. “We welcome David to our exe

GlobeNewswire 4 months ago

ICU
+2.28%
ICUCW

Performance Overview

Return	ICU	S&P 500
YTD	-50.47%	+12.10%
1-Year	-57.48%	+24.82%
3-Year	-97.78%	+26.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SeaStar Medical Holding Corporation (ICU)

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation

SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024

SeaStar Medical Announces 25-for-1 Reverse Stock Split

Seastar touts positive case studies for selective cytopheretic device

Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility

SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024

Q4 2023 Nuwellis Inc Earnings Call

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury

Unleash Massive Returns With These 3 Top Penny Stocks

SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Appoints David A. Green as Chief Financial Officer

Performance Overview